NTLA Reports Positive Phase 3 HAELO Data, 87% Attack Reduction, Initiates Rolling BLA for Lonvo-z, Resumes Patient Screening in MAGNITUDE ATTR Trials
Intellia Therapeutics, Inc · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · Now $14.07
-15% in 7d after detection
Post-detection moves
1h
—
1d
-3.0%
3d
-9.2%
7d
-15%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS